Skip to main content
. 2020 Jul 20;45(13):2267–2277. doi: 10.1038/s41386-020-0775-z

Fig. 4. Engagement of 5-HTR7 in shaping adult emotional behaviors.

Fig. 4

a 5-HTR7+/− and 5-HTR7−/− mice were treated orally with FLX (10 mg/kg/day in 3% sucrose solution; n = 16 and n = 22 for 5-HTR7+/− and 5-HTR7−/− mice, respectively) or vehicle (3% sucrose solution; n = 14 and n = 24 for 5-HTR7+/− and 5-HTR7−/− mice, respectively) during the critical period (P2–P14), to evaluate emotional behaviors in the adulthood (from P80). b Total distance traveled in the Open Field test (OF) (Main Effects treatment: F1,72 = 17.606; p < 0.0001), and time spent in the center of the arena (c) (Interaction treatment x genotype: F1,72 = 3.978; p < 0.05 in 5-HTR7+/− mice, FLX vs. control: F1,28 = 10.954; p < 0.003). d Latency to groom in the Splash Test (ST) (Main Effects treatment: F1,72 = 22.385; p < 0.0001). e The latency to feed in the Novelty Suppressed Feeding Test (NSF) (Main Effects treatment: F1,72 = 13.619; p < 0.0004). f Immobility time in the Forced Swim Test (FST) (Main Effects treatment: F1,72 = 13.209; p < 0.001). g Locomotor activity in a circular path (Main Effects treatment: F1,72 = 0.451; p = 0.50). h C57BL/6 mice were bilaterally injected with AAV-hSyn-5-HTR7-EGFP (OE; n = 14) or AAV-hSyn-EGFP (Sham; n = 14) in the PFC at P1. Behavioral measurements were carried out in these mice in the OF (i, j), ST (k), NSF (l) and FST (m), and locomotor activity (n), starting at P80. **p < 0.005 and ****p < 0.0001 in i–n.